AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34711225 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Imagery (MI) rehearsal exercise
Number of subjects: 17
Study 32833478 — intervention group
Group type: EXPERIMENTAL
Intervention: APPEAL intervention (3 monthly, individually administered sessions)
Number of subjects: 80
Study 32833478 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 80
Study 85069879 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 35
Study 85069879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 35967369 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine-tenofovir (FTC-TDF) or emtricitabine-tenofovir alafenamide (FTC-TAF)
Number of subjects: 144
Study 35967369 — intervention group
Group type: COMPARATOR
Intervention: Control specimens
Number of subjects: 144
Study 33681909 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified protocol combined with mindfulness treatment
Number of subjects: 31
Study 33681909 — intervention group
Group type: COMPARATOR
Intervention: Unified protocol alone
Number of subjects: 31
Study 33157497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-education (interactive education and consultancy provided by phone calls, text message, and digital education booklet) for one week
Number of subjects: 96
Study 33157497 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 96
Study 33157497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-education (experiment group)
Number of subjects: 96
Study 35363591 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate-coated indwelling pleural catheter (SNCIPC)
Number of subjects: 114
Study 35363591 — intervention group
Group type: COMPARATOR
Intervention: Standard uncoated catheter
Number of subjects: 114
Study 33772627 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID use in patients with preexisting renal impairment
Number of subjects: 18794
Study 33772627 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID use in patients without preexisting renal impairment
Number of subjects: 18794
Study 33772627 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID use in pooled cohort
Number of subjects: 18794
Study 32673785 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal subregion (V44-V74)
Number of subjects: 450
Study 32673785 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethra subregion (V68-V72)
Number of subjects: 450
Study 32673785 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethra subregion (V56-V68)
Number of subjects: 450
Study 32673785 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethra subregion (V14-V64)
Number of subjects: 450
Study 32673785 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethra (V71)
Number of subjects: 450
Study 32673785 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior bladder (V65)
Number of subjects: 450
Study 32673785 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior bladder (V39)
Number of subjects: 450
Study 34087753 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-disclosure group
Number of subjects: 556
Study 34087753 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 556
Study 34371121 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention (Taste Education program)
Number of subjects: 81
Study 34371121 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 81
Study 32512124 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 99
Study 32512124 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 99
Study 35636471 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Templates (DT)
Number of subjects: 70
Study 35636471 — intervention group
Group type: COMPARATOR
Intervention: Digital Occlusal Splints (DOS)
Number of subjects: 70
Study 32970526 — intervention group
Group type: EXPERIMENTAL
Intervention: Fay and Graubard
Number of subjects: 0
Study 32970526 — intervention group
Group type: EXPERIMENTAL
Intervention: Kauermann and Carroll (approximation)
Number of subjects: 0
Study 34727272 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 187
Study 33047859 — intervention group
Group type: COMPARATOR
Intervention: BI 655064 single doses (80-240 mg)
Number of subjects: 21
Study 33047859 — intervention group
Group type: COMPARATOR
Intervention: BI 655064 repeated doses (240 mg once weekly for 4 weeks)
Number of subjects: 21
Study 33047859 — intervention group
Group type: COMPARATOR
Intervention: BI 655064 (240 mg)
Number of subjects: 21
Study 33047859 — intervention group
Group type: COMPARATOR
Intervention: BI 655064 (≥120 mg)
Number of subjects: 21
Study 33047859 — intervention group
Group type: COMPARATOR
Intervention: BI 655064
Number of subjects: 21
Study 36064990 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective guided self-help intervention
Number of subjects: 108
Study 36064990 — intervention group
Group type: COMPARATOR
Intervention: Behavioral intervention
Number of subjects: 108
Study 34853380 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 108
Study 34853380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 108
Study 34853380 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 108
Study 35685052 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin‐A injections and exercise
Number of subjects: 30
Study 35685052 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin‐A injections, exercise, and dry needling
Number of subjects: 30
Study 34907724 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 60
Study 34907724 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (200 mg oral daily)
Number of subjects: 60
Study 33021081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenoside H dripping pill (GH) at 7.8 mg
Number of subjects: 0
Study 33021081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenoside H dripping pill (GH) at 15.6 mg
Number of subjects: 0
Study 33021081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenoside H dripping pill (GH) at 31.2 mg
Number of subjects: 0
Study 33021081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenoside H dripping pill (GH) (multiple doses)
Number of subjects: 0
Study 36112733 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared bipolar radiofrequency (IR-RF)
Number of subjects: 27
Study 36112733 — intervention group
Group type: EXPERIMENTAL
Intervention: 1540 nm Er: glass non-ablative fractional laser (NAFL)
Number of subjects: 27
Study 36112733 — intervention group
Group type: EXPERIMENTAL
Intervention: 1927 nm thulium-doped NAFL
Number of subjects: 27
Study 33972129 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program (5 individual sessions, educational booklets, 4 phone-call follow-ups over 3 months)
Number of subjects: 86
Study 33972129 — intervention group
Group type: COMPARATOR
Intervention: Routine care (comparison group)
Number of subjects: 86
Study 35568681 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch technique LT (NT group)
Number of subjects: 84
Study 32437229 — intervention group
Group type: EXPERIMENTAL
Intervention: Active arm (screening)
Number of subjects: 2
Study 32437229 — intervention group
Group type: COMPARATOR
Intervention: Control arm (usual care)
Number of subjects: 2
Study 34069951 — intervention group
Group type: COMPARATOR
Intervention: Intravesical administration of liposome-encapsulated BoNT-A
Number of subjects: 6
Study 34069951 — intervention group
Group type: COMPARATOR
Intervention: Intravesical administration of TC-3 hydrogel embedded BoNT-A
Number of subjects: 6
Study 34069951 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic energy shock wave (ESW) after BoNT-A intravesical administration
Number of subjects: 6
Study 32521325 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab treatment
Number of subjects: 0
Study 35900529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 68
Study 35900529 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermocoagulation
Number of subjects: 68
Study 33863635 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin plus vitamin E (α‐Tocopherol) 400 units daily
Number of subjects: 52
Study 33863635 — intervention group
Group type: COMPARATOR
Intervention: Colistin alone
Number of subjects: 52
Study 32384288 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 72
Study 32384288 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 72
Study 33218510 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial induction therapy (MIT)
Number of subjects: 40
Study 33218510 — intervention group
Group type: COMPARATOR
Intervention: Pain neuroscience education (PNE)
Number of subjects: 40
Study 33218510 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MIT and PNE
Number of subjects: 40
Study 34891216 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) + CoQ10 (2 × 200 mg/day)
Number of subjects: 26
Study 34891216 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) + Placebo
Number of subjects: 26
Study 34891216 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Placebo
Number of subjects: 26
Study 33722871 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day
Number of subjects: 1120
Study 33722871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1120
Study 32040960 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplex vaccine
Number of subjects: 102
Study 32040960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 33044366 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonperiodized combined training (NG; n = 8)
Number of subjects: 34
Study 33044366 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear periodized combined training (PG; n = 11)
Number of subjects: 34
Study 33044366 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; n = 15)
Number of subjects: 34
Study 32942960 — intervention group
Group type: EXPERIMENTAL
Intervention: FF+PT (FastFES with individualized verbal instructions and faded feedback)
Number of subjects: 9
Study 32942960 — intervention group
Group type: COMPARATOR
Intervention: FF (FastFES)
Number of subjects: 9
Study 32942960 — intervention group
Group type: COMPARATOR
Intervention: FF+Var (FastFES with variable gait speed and FES timing)
Number of subjects: 9
Study 32881796 — intervention group
Group type: EXPERIMENTAL
Intervention: iENGAGE intervention (four face-to-face sessions)
Number of subjects: 371
Study 32881796 — intervention group
Group type: COMPARATOR
Intervention: Standard of care control arm
Number of subjects: 371
Study 35778675 — intervention group
Group type: EXPERIMENTAL
Intervention: Shelf-stable MDCF prototypes
Number of subjects: 0
Study 35778675 — intervention group
Group type: COMPARATOR
Intervention: Freshly prepared MDCF-2
Number of subjects: 0
Study 34164794 — intervention group
Group type: EXPERIMENTAL
Intervention: HTL0018318 15 mg alone
Number of subjects: 42
Study 34164794 — intervention group
Group type: EXPERIMENTAL
Intervention: HTL0018318 25 mg alone
Number of subjects: 42
Study 34164794 — intervention group
Group type: COMPARATOR
Intervention: HTL0018318 alone
Number of subjects: 42
Study 34164794 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 42
Study 34164794 — intervention group
Group type: EXPERIMENTAL
Intervention: HTL0018318 and donepezil combination
Number of subjects: 42
Study 33372602 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive air-polishing using nozzle+erythritol powder (test group, n=21)
Number of subjects: 42
Study 33372602 — intervention group
Group type: COMPARATOR
Intervention: Subgingival instrumentation only (control group, n=21)
Number of subjects: 42
Study 36474379 — intervention group
Group type: EXPERIMENTAL
Intervention: NLD probing with momentary probe indwelling for 5 minutes (Group B)
Number of subjects: 204
Study 36474379 — intervention group
Group type: COMPARATOR
Intervention: NLD probing without momentary probe indwelling (Group A)
Number of subjects: 204
Study 33906642 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated net (ITN) ownership
Number of subjects: 302
Study 33906642 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated net (ITN) availability
Number of subjects: 302
Study 33906642 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with ITN use
Number of subjects: 302
Study 32895343 — intervention group
Group type: EXPERIMENTAL
Intervention: BeHaS program (12-week, one-hour program per week and two individual health consultations)
Number of subjects: 43
Study 32895343 — intervention group
Group type: COMPARATOR
Intervention: Control group (two sessions about metabolic syndrome and two individual health consultations)
Number of subjects: 43
Study 36308902 — intervention group
Group type: EXPERIMENTAL
Intervention: Diterpene Ginkgolides Meglumine injection (DGMI)
Number of subjects: 314
Study 36308902 — intervention group
Group type: COMPARATOR
Intervention: Ginaton
Number of subjects: 314
Study 33648563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) administration for 4 consecutive days
Number of subjects: 138
Study 33648563 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%) for 4 consecutive days
Number of subjects: 138
Study 33648563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) administration
Number of subjects: 138
Study 34793406 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (CBT)
Number of subjects: 278
Study 34793406 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered pain education (EDU)
Number of subjects: 278
Study 36034802 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/week of PEG‐rhGH
Number of subjects: 0
Study 36034802 — intervention group
Group type: COMPARATOR
Intervention: 0.14 mg/kg/week of PEG‐rhGH
Number of subjects: 0
Study 34268900 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care (SoC) plus wearing a PA monitoring device (Fitbit Charge 3) with personalized step goals, feedback and motivation
Number of subjects: 180
Study 34268900 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) only
Number of subjects: 180
Study 32292179 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app for CPR guidance
Number of subjects: 26
Study 32292179 — intervention group
Group type: COMPARATOR
Intervention: PALS pocket reference cards
Number of subjects: 26
Study 35998550 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery-Radiotherapy Interval (SRI) > 210 days
Number of subjects: 584
Study 35998550 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-Radiotherapy Interval (CRI) > 42 days
Number of subjects: 584
Study 35998550 — intervention group
Group type: COMPARATOR
Intervention: Surgery-Radiotherapy Interval (SRI) < 180 or 180-210 days
Number of subjects: 584
Study 35998550 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy-Radiotherapy Interval (CRI) < 28 or 28-42 days
Number of subjects: 584
Study 35998550 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI and CRI
Number of subjects: 584
Study 33533941 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA) cohort
Number of subjects: 30706
Study 33533941 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA) cohort not receiving RA therapy
Number of subjects: 30706
Study 33533941 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-RA cohort)
Number of subjects: 30706
Study 32429965 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated modular teaching using different problem-based teaching methods (e.g., flipped classroom, team-based learning)
Number of subjects: 100
Study 32429965 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated modular teaching
Number of subjects: 100
Study 33989234 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep anterior lamellar keratoplasty
Number of subjects: 0
Study 33989234 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet stripping automated endothelial keratoplasty
Number of subjects: 0
Study 33989234 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty
Number of subjects: 0
Study 33989234 — intervention group
Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PKP)
Number of subjects: 0
Study 33989234 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nonsteroid agents (tacrolimus and anti-vascular endothelial growth factor)
Number of subjects: 0
Study 33651108 — intervention group
Group type: EXPERIMENTAL
Intervention: Requests with supporting evidence for overall survival (OS) benefit
Number of subjects: 5809
Study 33651108 — intervention group
Group type: EXPERIMENTAL
Intervention: Requests with supporting evidence for progression-free survival (PFS) benefit
Number of subjects: 5809
Study 33651108 — intervention group
Group type: COMPARATOR
Intervention: Requests without supporting evidence for OS or PFS benefit
Number of subjects: 5809
Study 33651108 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall association of OS benefit with reimbursement
Number of subjects: 5809
Study 34618629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontraditional classroom (NTC) pedagogies comprising e-learning, peer teaching, and flipped classroom
Number of subjects: 0
Study 34618629 — intervention group
Group type: COMPARATOR
Intervention: Textbook-based preview (Control)
Number of subjects: 0
Study 33827488 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-produced audio-visual animation introduction (Group A)
Number of subjects: 100
Study 33827488 — intervention group
Group type: COMPARATOR
Intervention: Control group without audio-visual animation introduction (Group C)
Number of subjects: 100
Study 35714806 — intervention group
Group type: EXPERIMENTAL
Intervention: Protons (20x3.3Gy(RBE))
Number of subjects: 92
Study 35714806 — intervention group
Group type: COMPARATOR
Intervention: Carbon ions (20x3.3Gy(RBE))
Number of subjects: 92
Study 32702169 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropifexor 60 µg
Number of subjects: 20
Study 32702169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 35642398 — intervention group
Group type: EXPERIMENTAL
Intervention: rock salt aerosol therapy
Number of subjects: 452
Study 35642398 — intervention group
Group type: COMPARATOR
Intervention: conventional comprehensive treatment
Number of subjects: 452
Study 34827460 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory biofeedback prosthesis (Auditory Foot)
Number of subjects: 0
Study 34827460 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32819390 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT) consisting of 8 cycles of capecitabine plus oxaliplatin
Number of subjects: 1320
Study 32819390 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up according to guidelines
Number of subjects: 1320
Study 34811509 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diet plus 30g/day of pecan nuts (pecan nut group [PNG])
Number of subjects: 204
Study 34811509 — intervention group
Group type: COMPARATOR
Intervention: Healthy diet (control group [CG])
Number of subjects: 204
Study 34811509 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diet plus 30mL/day of extra-virgin olive oil (olive oil group [OOG])
Number of subjects: 204
Study 32780237 — intervention group
Group type: EXPERIMENTAL
Intervention: SpyGlass-guided laser lithotripsy
Number of subjects: 157
Study 32780237 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic common bile duct exploration (LCBDE)
Number of subjects: 157
Study 35551928 — intervention group
Group type: COMPARATOR
Intervention: Placebo alcohol and placebo cannabis (<0.1% THC)
Number of subjects: 28
Study 35551928 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (target breath alcohol content [BrAC] 80 mg/dL) and placebo cannabis
Number of subjects: 28
Study 35551928 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo alcohol and active cannabis (12.5% THC)
Number of subjects: 28
Study 35551928 — intervention group
Group type: EXPERIMENTAL
Intervention: Active alcohol and cannabis
Number of subjects: 28
Study 34171133 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention based on Cox's interaction model of client health behaviour
Number of subjects: 77
Study 34171133 — intervention group
Group type: COMPARATOR
Intervention: Routine health education
Number of subjects: 77
Study 32568799 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel technique using a partial-thickness hinge punch for DMEK graft preparation
Number of subjects: 18
Study 32568799 — intervention group
Group type: EXPERIMENTAL
Intervention: Single user in an eye bank setting
Number of subjects: 18
Study 616764746 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of a competition element to the journal club
Number of subjects: 1674
Study 616764746 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendees of the journal club
Number of subjects: 1674
Study 616764746 — intervention group
Group type: EXPERIMENTAL
Intervention: Presenters in the journal club
Number of subjects: 1674
Study 33915492 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile banking savings intervention promoting savings for goals and emergency expenses
Number of subjects: 0
Study 33915492 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile banking savings intervention
Number of subjects: 0
Study 36180886 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models using DNA methylation-regulated genes (LightGBM, XGBoost, Random Forest)
Number of subjects: 2085
Study 36180886 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation and expression statuses of hub genes in monocytes
Number of subjects: 2085
Study 34215712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Program (8 sessions, 90 to 120 minutes each, over 8 weeks)
Number of subjects: 30
Study 34215712 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 30
Study 32389476 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous gradual weaning program (CG)
Number of subjects: 60
Study 32389476 — intervention group
Group type: COMPARATOR
Intervention: Multi‐step gradual weaning program (MG)
Number of subjects: 60